New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
January 7, 2014
10:02 EDTCOTY, TEVA, RGP, EGHT, BIN, WWAV, NMBL, ACMP, JAH, TEX, TCO, SGNT, AGN, CQP, MYL, PRGO, O, AKRX, ACT, ACRX, ANIPOn The Fly: Analyst Initiation Summary
Today's noteworthy initiations include: ANI Pharmaceuticals (ANIP) initiated with a Buy at Roth Capital... AcelRx (ACRX) initiated with an Outperform at RBC Capital... Actavis (ACT) initiated with an Outperform at RBC Capital... Akorn (AKRX) initiated with an Outperform at RBC Capital... Allergan (AGN) initiated with an Outperform at RBC Capital... Cheniere Energy Partners (CQP) initiated with an Outperform at Credit Suisse... Mylan (MYL) initiated with an Outperform at RBC Capital... Perrigo (PRGO) initiated with a Top Pick at RBC Capital... Realty Income (O) initiated with an Outperform at Oppenheimer... Sagent Pharmaceuticals (SGNT) initiated with an Underperform at RBC Capital... Taubman Centers (TCO) initiated with a Perform at Oppenheimer... Terex (TEX) initiated with a Hold at Jefferies... Teva (TEVA) initiated with a Sector Perform at RBC Capital... Regency Energy Partners (RGP) reinstated with an Outperform at Credit Suisse... 8x8, Inc. (EGHT) initiated with a Buy at Needham... Progressive Waste (BIN) initiated with an Underperform at Macquarie... WhiteWave Foods (WWAV) reinstated with an Overweight at JPMorgan... Nimble Storage (NMBL) initiated with a Buy at Stifel... Access Midstream (ACMP) coverage assumed with an Outperform at Credit Suisse... Jarden (JAH) initiated with an Outperform at RBC Capital... Coty (COTY) initiated with a Sector Perform at RBC Capital.
News For ANIP;ACRX;ACT;AKRX;AGN;CQP;MYL;PRGO;O;SGNT;TCO;TEX;TEVA;RGP;EGHT;BIN;WWAV;NMBL;ACMP;JAH;COTY From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | 4 | all recent news | >>
October 10, 2014
10:01 EDTNMBLOn The Fly: Analyst Initiation Summary
Today's noteworthy initiations include: 2U (TWOU) initiated with an Outperform at Pacific Crest... Bloomin' Brands (BLMN) initiated with an Outperform at BMO Capital... Brinker (EAT) initiated with a Market Perform at BMO Capital... Buffalo Wild Wings (BWLD) initiated with an Outperform at BMO Capital... Chipotle (CMG) initiated with a Market Perform at BMO Capital... Chuy's (CHUY) initiated with a Market Perform at BMO Capital... Darden (DRI) initiated with a Market Perform at BMO Capital... EMC (EMC) initiated with a Buy at Jefferies... EPR Properties (EPR) initiated with a Buy at BofA/Merrill... HP (HPQ) initiated with a Hold at Jefferies... IBM (IBM) initiated with an Underperform at Jefferies... McDermott (MDR) initiated with an In-Line at Imperial Capital... NetApp (NTAP) initiated with a Hold at Jefferies... New Residential (NRZ) initiated with a Neutral at Piper Jaffray... Nimble Storage (NMBL) initiated with a Buy at Jefferies... Noodles & Company (NDLS) initiated with an Outperform at BMO Capital... PDC Energy (PDCE) initiated with an Overweight at Stephens... Panera Bread (PNRA) initiated with a Market Perform at BMO Capital... Pioneer Natural (PXD) initiated with an Outperform at Imperial Capital... Resource America (REXI) initiated with a Buy at MLV & Co.... Rex Energy (REXX) initiated with an Overweight at Stephens... Seagate (STX) initiated with a Buy at Jefferies... Silicon Motion (SIMO) initiated with a Buy at Brean Capital... Texas Roadhouse (TXRH) initiated with a Market Perform at BMO Capital... W.P. Carey (WPC) initiated with a Neutral at BofA/Merrill... Wayfair (W) initiated with a Buy at Janney Capital...Western Digital (WDC) initiated with a Buy at Jefferies... Yelp (YELP) initiated with a Buy at Sterne Agee.
07:37 EDTAGN, ACTActavis more likely partner than Valeant if Allergan merges, says UBS
Subscribe for More Information
07:35 EDTAGNAllergan price target raised to $224-$225, from $198-$199 at Wells Fargo
Wells Fargo increased its price target on Allergan after the company pre-released better-than-expected revenue and EPS, and raised its 2014-2016 EPS guidance. The firm keeps an Outperform rating on the shares.
07:16 EDTAGNAmerican Society of Plastic Surgeons to hold annual meeting
Annual Meeting of ASPS is being held in Chicago on October 10-14.
October 9, 2014
16:59 EDTNMBLJefferies initiates IT Hardware space, names Western Digital top pick
Subscribe for More Information
16:22 EDTNMBLNimble Storage initiated with a Buy at Jefferies
Subscribe for More Information
16:11 EDTTEVAAlexza reports 32,278 Adasuve units shipped to Teva in Q3
Subscribe for More Information
15:16 EDTRGPRegency Energy, Oneok interested in Nuevo Midstream sale, Bloomberg reports
Subscribe for More Information
14:21 EDTAGNAllergan in good position to be patient given raised outlook, says BMO Capital
After speaking with Allergan's (AGN) CEO and CFO, BMO Capital believes the company is increasing its intrinsic value with its raised earnings guidance and that it is in a good position to be patient given that Valeant (VRX) most recent bid represents an 8% discount to Allergan's current share price. BMO said it is reviewing its forecasts for Allergan after the guidance increase, noting that it previously valued Allergan at $230 per share on a standalone basis. The firm maintains its Outperform rating on the stock.
12:28 EDTACT, AGNAllergan price target raised to $230 from $210 at BTIG
BTIG said it expected Allergan to beat the consensus forecast for Q3 EPS, but not by as much as it did, and the firm did not expect the company to raise its future EPS outlook yet again. BTIG feels the stock's move higher indicates Valeant (VRX) or Actavis (ACT) would need to bid above $200 if they hope to buy the company. BTIG maintains its Buy rating on Allergan and raised its price target on the stock to $230 from $210.
11:17 EDTNMBLNimble Storage management to meet with Oppenheimer
Subscribe for More Information
11:14 EDTACT, AGNAllergan raises outlook again as Valeant pursuit continues
Drug maker Allergan (AGN) this morning preannounced stronger than expected results and again raised its fiscal year profit guidance. The beat and raise results come after The Wall Street Journal reported on Tuesday that drug maker Valeant (VRX) and hedge fund Pershing Square intend to raise their previous bid for Allergan by $15 per share to about $191. Meanwhile, also on Tuesday, Reuters said that drug maker Actavis (ACT) plans to make a new merger offer to Allergan, and sources indicated to the news service that Allergan may be willing to consider an offer from Actavis if the bid is for more than $200 per share. WHAT'S NEW: Allergan estimated that its third quarter earnings per share would come in at $1.76-$1.78, versus analysts' consensus estimate of $1.48. The drug maker had previously provided Q3 EPS guidance of $1.44-$1.47. Allergan raised its fiscal 2014 EPS guidance to $6.20-$6.25 from $5.74-$5.80. Analysts' consensus estimate was $5.81. This is the fourth time that Allergan has raised its guidance this year. Allergan said that its markets have been strong around the world, while it is gaining market share in most categories. ANALYST REACTION: In a note to investors today, Wells Fargo analyst Larry Biegelsen wrote that, in the wake of Allergan's guidance increase, the company's price to earnings multiple could expand to 22x its estimated 2016 earnings, up from its current multiple of 19x. In addition to the raised guidance, a potential accretive acquisition by Allergan and the possibility that it will be acquired make such an increase in the multiple "quite possible," Biegelsen contended. He kept an Outperform rating on the stock. WHAT'S NOTABLE: Allergan has reportedly held advanced talks about acquiring another company in the sector, Salix (SLXP), although CNBC's David Faber on October 2 reported that the talks between the two companies about a merger had "cooled considerably." PRICE ACTION: In late morning trading, Allergan rose fractionally to $191.06 while Valeant slid 1.5% to $124.08.
10:27 EDTACRXAcelRx management to meet with Guggenheim
Subscribe for More Information
10:00 EDTAGNOn The Fly: Analyst Initiation Summary
Subscribe for More Information
08:50 EDTAGN, ACTAllergan shares have further upside, says Wells Fargo
Subscribe for More Information
06:49 EDTAGNAllergan cites momentum from robust growth of worldwide markets
The company also cites increases in market share in most categories, many regulatory approvals for new products in the U.S. and internationally, and targeted investments to create and grow new products and new categories. Exceptional growth in EPS from the acceleration in sales but also in leveraging of sales and marketing expenditures. The benefits from Allerganís previously announced restructuring program will be reflected in the Companyís actual results beginning in the fourth quarter of 2014 and continuing through 2015.
06:47 EDTAGNAllergan sees FY16 non-GAAP EPS $10.25
06:47 EDTAGNAllergan sees FY15 non-GAAP EPS $8.60, consensus $8.25
Subscribe for More Information
06:47 EDTAGNAllergan sees FY14 non-GAAP EPS $6.20-$6.25, consensus $5.81
Subscribe for More Information
06:46 EDTAGNAllergan raises Q3 EPS to $1.76-$1.78 from $1.44-$1.47, consensus $1.48
Expects Q3 product net sales to increase in excess of 17% in dollars compared to product net sales from 3Q13.
1 | 2 | 3 | 4 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use